ArticleIndian journal of ophthalmology2026
Phaco-endocyclophotocoagulation versus phaco-trabeculectomy in advanced glaucoma: A pilot study.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the safety and efficacy of combining minimally invasive glaucoma surgery (MIGS) endocyclophotocoagulation (ECP) in advanced primary glaucomas and compare them with those of the current gold standard of phaco-trabeculectomy (PT).
methodsThis is a retrospective study of subjects with advanced primary glaucomas (primary open angle glaucoma and primary angle closure glaucoma), more than 30 years, and who underwent ECP or trabeculectomy with Mitomycin C along with phaco-surgery. The primary outcome measure was IOP. The secondary outcomes were the number of anti-glaucoma medications (AGMs), best corrected visual acuity (BCVA), total success (defined as complete and qualified), complications, and interventions for these.
resultsTwenty-eight eyes with phaco-ECP and a mean follow-up of 18 months were compared to 24 eyes that underwent PT (mean follow-up of 16 months). IOP reduced from 24.9 ± 12.9 to 14.0 ± 2.3 mmHg in the former group, and from 26.7 ± 8.7 to 13.7 ± 3.0 mmHg in the latter (p=.667); AGM was reduced from 3.6 ± 1.0 to 0.9 ± 1.0 and 3.5 ± 1.1 to 1.4 ± 1.5 in each group, respectively (p=.624). No sight-threatening complications occurred in either group; however, BCVA improved significantly in the phaco-ECP group (p=.04). Though complications were more in the PT group, and so were the interventions (excluding suturelysis) they were marginally short of reaching significance (p=.05). No loss of vision occurred in either group. There were two failures in the PT group.
conclusionCombining ECP with phaco has the potential to be as effective as the current gold standard in advanced primary glaucomas. It is safer with significantly improved BCVA and a much-reduced need for any interventions. Larger studies and longer follow-ups are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.